Search Results - "Panitch, H"

Differential diagnosis of suspected multiple sclerosis: a consensus approach by Miller, DH, Weinshenker, BG, Filippi, M, Banwell, BL, Cohen, JA, Freedman, MS, Galetta, SL, Hutchinson, M, Johnson, RT, Kappos, L, Kira, J, Lublin, FD, McFarland, HF, Montalban, X, Panitch, H, Richert, JR, Reingold, SC, Polman, CH

“…Background and objectives Diagnosis of multiple sclerosis (MS) requires exclusion of diseases that could better explain the clinical and paraclinical findings…”
Get full text

Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate by Ford, C., Goodman, AD, Johnson, K., Kachuck, N., Lindsey, JW, Lisak, R., Luzzio, C., Myers, L., Panitch, H., Preiningerova, J., Pruitt, A., Rose, J., Rus, H., Wolinsky, J.

“…The ongoing US Glatiramer Acetate (GA) Trial is the longest evaluation of continuous immunomodulatory therapy in relapsing—remitting multiple sclerosis (RRMS)…”
Get full text

Randomized, comparative study of interferon β-1a treatment regimens in MS: The EVIDENCE Trial by PANITCH, H, GOODIN, D. S, FRANCIS, G, CHANG, P, COYLE, P. K, O'CONNOR, P, MONAGHAN, E, LI, D, WEINSHENKER, B

Get full text

A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients by Ford, C C, Johnson, K P, Lisak, R P, Panitch, H S, Shifroni, G, Wolinsky, J S

“…A decade of continuous glatiramer acetate (GA) use by relapsing remitting multiple sclerosis (RRMS) patients was evaluated in this ongoing, prospective study,…”
Get full text

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability by JOHNSON, K. P, BROOKS, B. R, VOLLMER, T, WEINER, L. P, WOLINSKY, J. S, COHEN, J. A, FORD, C. C, GOLDSTEIN, J, LISAK, R. P, MYERS, L. W, PANITCH, H. S, ROSE, J. W, SCHIFFER, R. B

Get full text

Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis by Vollmer, T, Panitch, H, Bar-Or, A, Dunn, J, Freedman, MS, Gazda, SK, Campagnolo, D, Deutsch, F, Arnold, DL

“…Forty relapsing multiple sclerosis patients with 1–15 gadolinium (Gd)-enhancing lesions on screening brain magnetic resonance imaging (MRI) and Expanded…”
Get full text

Influence of infection on exacerbations of multiple sclerosis by Panitch, H S

“…Exacerbations of multiple sclerosis (MS) are triggered by exogenous events, the best documented being viral upper respiratory infections (URIs), which can…”
Get more information

Developmental changes in chest wall compliance in infancy and early childhood by Papastamelos, C, Panitch, H B, England, S E, Allen, J L

“…Development of chest wall stiffness between infancy and adulthood has important consequences for respiratory system function. To test the hypothesis that there…”
Get more information

Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment by Polman, C H, Reingold, S C, Barkhof, F, Calabresi, P A, Clanet, M, Cohen, J A, Cutter, G R, Freedman, M S, Kappos, L, Lublin, F D, McFarland, H F, Metz, L M, Miller, A E, Montalban, X, O'Connor, P W, Panitch, H, Richert, J R, Petkau, J, Schwid, S R, Sormani, M P, Thompson, A J, Weinshenker, B G, Wolinsky, J S

“…The increasing number of established effective therapies for relapsing multiple sclerosis (MS) and emerging consensus for early treatment raise practical…”
Get full text

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years by Johnson, K P, Brooks, B R, Ford, C C, Goodman, A, Guarnaccia, J, Lisak, R P, Myers, L W, Panitch, H S, Pruitt, A, Rose, J W, Kachuck, N, Wolinsky, J S

“…In a randomized, placebo-controlled, double-blind study, glatiramer acetate (Copaxone®) reduced the relapse rate and slowed accumulation of disability for…”
Get full text

Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS by Arnold, D. L., Campagnolo, D., Panitch, H., Bar-Or, A., Dunn, J., Freedman, M. S., Gazda, S. K., Vollmer, T.

“…Background Glatiramer acetate (GA) therapy following brief, low-dose induction with mitoxantrone was safe and more effective than GA alone in suppressing…”
Get full text

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years by Johnson, K.P., Brooks, B.R., Ford, C.C., Goodman, A., Guarnaccia, J., Lisak, R.P., Myers, L.W., Panitch, H.S., Pruitt, A., Rose, J.W., Kachuck, N., Wolinsky, J.S.

“…In a randomized, placebo-controlled, double-blind study, glatiramer acetate (Copaxone) reduced the relapse rate and slowed accumulation of disability for…”
Get full text

MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group

“…To assess the ability of baseline MRI characteristics to predict the early development of clinically definite MS (CDMS) and combined CDMS/MRI outcomes in 190…”
Get full text

The effects of 4-aminopyridine in multiple sclerosis patients : results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial by BEVER, C. T, YOUNG, D, FOSSLER, M. J, DEVANE, J, JOHNSON, K. P, ANDERSON, P. A, KRUMHOLZ, A, CONWAY, R. N, LESLIE, J, EDDINGTON, N, PLAISANCE, K. I, PANITCH, H. S, DHIB-JALBUT, S

“…Because 4-aminopyridine (AP) improves residual deficits in some multiple sclerosis (MS) patients but has a narrow toxic-to-therapeutic margin, we compared the…”
Get full text

Intramedullary spinal cord abscess in a healthy woman by APPLEBEE, A, RAMUNDO, M, KIRKPATRICK, B. D, FRIES, T. J, PANITCH, H

Get full text

Serial combination therapy: is immune modulation in multiple sclerosis enhanced by initial immune suppression? by Bar-Or, A, Oger, J, Gibbs, E, Niino, M, Aziz, T, Renoux, C, Alatab, S, Shi, FD, Campagnolo, D, Jalili, F, Rhodes, S, Yamashita, T, Fan, B, Freedman, MS, Panitch, H, Arnold, DL, Vollmer, T

“…Background Although the concept that an initial course of immune-suppression facilitates subsequent immune-modulation (such as Th1 to Th2 deviation) is…”
Get full text

Interferons in multiple sclerosis : a review of the evidence by PANITCH, H. S

“…Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system, characterised clinically by relapses and remissions, and…”
Get full text

Exacerbations of multiple sclerosis in patients treated with gamma interferon by Panitch, H S, Hirsch, R L, Haley, A S, Johnson, K P

“…In an open, randomised study, 18 patients with clinically definite, relapsing-remitting multiple sclerosis (MS) received 1 microgram, 30 micrograms, or 1000…”
Get more information

Interferon beta-1b serum levels in multiple sclerosis patients following subcutaneous administration by Khan, O A, Xia, Q, Bever, C T, Johnson, K P, Panitch, H S, Dhib-Jalbut, S S

“…Recombinant interferon beta-1b (rIFN beta) reduces the frequency of exacerbations in relapsing-remitting MS when administered subcutaneously on alternate days…”
Get full text

Bronchiolitis in infants by Panitch, H B

“…Bronchiolitis is a common cause of wheezing among infants. Respiratory syncytial virus (RSV) is the most common infectious agent to cause bronchiolitis, and…”
Get full text